 Christene Huang
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Swine | 40 | 2022 | 706 | 2.330 |
Why?
| | Diphtheria Toxin | 13 | 2020 | 51 | 2.160 |
Why?
| | Immunotoxins | 12 | 2022 | 33 | 2.030 |
Why?
| | Swine, Miniature | 24 | 2016 | 71 | 1.850 |
Why?
| | Transplantation Conditioning | 9 | 2016 | 152 | 1.310 |
Why?
| | Transplantation Chimera | 11 | 2016 | 51 | 1.240 |
Why?
| | Galectin 3 | 3 | 2022 | 18 | 1.230 |
Why?
| | Lymphocyte Depletion | 9 | 2016 | 115 | 1.230 |
Why?
| | Blood Component Removal | 2 | 2018 | 30 | 1.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 11 | 2016 | 524 | 1.120 |
Why?
| | CD3 Complex | 5 | 2013 | 92 | 1.060 |
Why?
| | Graft vs Host Disease | 6 | 2016 | 210 | 0.890 |
Why?
| | Swine Diseases | 5 | 2015 | 8 | 0.840 |
Why?
| | Recombinant Fusion Proteins | 10 | 2020 | 616 | 0.810 |
Why?
| | Skin Transplantation | 5 | 2016 | 58 | 0.730 |
Why?
| | Lymphoproliferative Disorders | 5 | 2015 | 46 | 0.710 |
Why?
| | Graft Rejection | 9 | 2016 | 533 | 0.710 |
Why?
| | Bone Marrow Transplantation | 7 | 2015 | 241 | 0.680 |
Why?
| | Isoantibodies | 5 | 2016 | 52 | 0.680 |
Why?
| | Histocompatibility Antigens | 3 | 2015 | 100 | 0.640 |
Why?
| | Animals | 58 | 2023 | 32123 | 0.620 |
Why?
| | Interleukin-2 | 5 | 2020 | 414 | 0.610 |
Why?
| | Cell Transplantation | 2 | 2010 | 37 | 0.610 |
Why?
| | Transplantation, Homologous | 8 | 2016 | 398 | 0.600 |
Why?
| | T-Lymphocytes, Regulatory | 6 | 2022 | 340 | 0.590 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 193 | 0.580 |
Why?
| | Immunity, Humoral | 3 | 2015 | 111 | 0.560 |
Why?
| | Transplantation, Haploidentical | 1 | 2016 | 7 | 0.560 |
Why?
| | Lymphocyte Transfusion | 1 | 2016 | 19 | 0.560 |
Why?
| | Blood Donors | 1 | 2016 | 89 | 0.510 |
Why?
| | Receptors, CCR4 | 5 | 2020 | 15 | 0.500 |
Why?
| | Graft Survival | 8 | 2015 | 481 | 0.490 |
Why?
| | Transplantation Immunology | 4 | 2012 | 31 | 0.490 |
Why?
| | T-Lymphocytes | 7 | 2015 | 1758 | 0.480 |
Why?
| | Transplantation Tolerance | 5 | 2014 | 31 | 0.480 |
Why?
| | Autoimmunity | 2 | 2022 | 823 | 0.470 |
Why?
| | Cell Lineage | 2 | 2006 | 311 | 0.460 |
Why?
| | Pichia | 8 | 2017 | 19 | 0.450 |
Why?
| | Immunity, Cellular | 3 | 2013 | 263 | 0.440 |
Why?
| | Cyclosporine | 7 | 2016 | 169 | 0.430 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 5 | 2020 | 66 | 0.430 |
Why?
| | Tissue Engineering | 1 | 2016 | 366 | 0.420 |
Why?
| | Inbreeding | 2 | 2009 | 16 | 0.390 |
Why?
| | Antibodies | 2 | 2012 | 374 | 0.370 |
Why?
| | Inflammation | 4 | 2022 | 2503 | 0.370 |
Why?
| | Transplantation, Heterologous | 4 | 2021 | 188 | 0.360 |
Why?
| | Whole-Body Irradiation | 4 | 2016 | 72 | 0.360 |
Why?
| | Hematopoietic Stem Cells | 4 | 2013 | 356 | 0.360 |
Why?
| | Umbilical Cord | 1 | 2010 | 80 | 0.360 |
Why?
| | Immune Tolerance | 5 | 2015 | 331 | 0.360 |
Why?
| | Transplantation | 2 | 2012 | 23 | 0.340 |
Why?
| | Flow Cytometry | 11 | 2020 | 1059 | 0.340 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 93 | 0.330 |
Why?
| | Liver Diseases | 2 | 2022 | 263 | 0.320 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2020 | 40 | 0.320 |
Why?
| | CTLA-4 Antigen | 3 | 2013 | 78 | 0.310 |
Why?
| | Thymus Gland | 4 | 2015 | 298 | 0.280 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2007 | 91 | 0.280 |
Why?
| | Immunosuppressive Agents | 5 | 2015 | 666 | 0.270 |
Why?
| | Chimerism | 1 | 2006 | 28 | 0.270 |
Why?
| | Bone Marrow | 2 | 2010 | 248 | 0.270 |
Why?
| | Hematologic Neoplasms | 1 | 2007 | 135 | 0.260 |
Why?
| | Fetal Blood | 1 | 2007 | 268 | 0.260 |
Why?
| | Galectins | 2 | 2022 | 22 | 0.250 |
Why?
| | Recombinant Proteins | 7 | 2020 | 1243 | 0.250 |
Why?
| | Cell Line, Tumor | 4 | 2017 | 2749 | 0.240 |
Why?
| | Papio | 3 | 2015 | 96 | 0.230 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1262 | 0.230 |
Why?
| | Fiber Optic Technology | 1 | 2023 | 17 | 0.230 |
Why?
| | Porphyrins | 1 | 2023 | 17 | 0.230 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 19 | 0.230 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2012 | 173 | 0.230 |
Why?
| | Skin | 3 | 2018 | 668 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2012 | 352 | 0.220 |
Why?
| | Antibody Specificity | 2 | 2017 | 180 | 0.210 |
Why?
| | Histocompatibility Testing | 4 | 2015 | 116 | 0.210 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.210 |
Why?
| | Hepatitis, Alcoholic | 1 | 2022 | 13 | 0.210 |
Why?
| | Muscle Stretching Exercises | 1 | 2022 | 17 | 0.200 |
Why?
| | Yoga | 1 | 2022 | 27 | 0.200 |
Why?
| | Meditation | 1 | 2022 | 34 | 0.200 |
Why?
| | Major Histocompatibility Complex | 4 | 2005 | 220 | 0.190 |
Why?
| | Skin Neoplasms | 2 | 2020 | 760 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 71 | 0.190 |
Why?
| | Leukapheresis | 3 | 2013 | 25 | 0.190 |
Why?
| | Immunoglobulin G | 2 | 2017 | 782 | 0.190 |
Why?
| | Histocompatibility | 3 | 2015 | 26 | 0.190 |
Why?
| | Mice, SCID | 5 | 2017 | 321 | 0.190 |
Why?
| | Endogenous Retroviruses | 1 | 2021 | 19 | 0.190 |
Why?
| | Spleen | 3 | 2007 | 491 | 0.180 |
Why?
| | Mice, Inbred NOD | 5 | 2017 | 562 | 0.180 |
Why?
| | Lymphoma | 1 | 2021 | 177 | 0.170 |
Why?
| | Colony-Forming Units Assay | 5 | 2006 | 92 | 0.170 |
Why?
| | Postoperative Complications | 3 | 2022 | 2167 | 0.170 |
Why?
| | Disease Models, Animal | 7 | 2015 | 3582 | 0.170 |
Why?
| | Amino Acid Sequence | 6 | 2015 | 2000 | 0.170 |
Why?
| | Hematologic Diseases | 2 | 2012 | 57 | 0.160 |
Why?
| | Time Factors | 7 | 2017 | 6186 | 0.160 |
Why?
| | Base Sequence | 6 | 2015 | 2120 | 0.160 |
Why?
| | B7-1 Antigen | 3 | 2013 | 54 | 0.160 |
Why?
| | Kidney Transplantation | 4 | 2005 | 560 | 0.160 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2793 | 0.160 |
Why?
| | Interleukin-3 | 2 | 2011 | 23 | 0.160 |
Why?
| | Freund's Adjuvant | 1 | 2018 | 17 | 0.160 |
Why?
| | Lymphocyte Culture Test, Mixed | 4 | 2014 | 43 | 0.150 |
Why?
| | Antibodies, Heterophile | 2 | 2015 | 13 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.150 |
Why?
| | Haplotypes | 2 | 2012 | 475 | 0.140 |
Why?
| | Papio hamadryas | 2 | 2013 | 5 | 0.140 |
Why?
| | Antibody Affinity | 1 | 2017 | 52 | 0.140 |
Why?
| | Antigens, CD19 | 1 | 2017 | 97 | 0.140 |
Why?
| | Heterografts | 2 | 2013 | 119 | 0.140 |
Why?
| | Antigen-Presenting Cells | 1 | 2016 | 152 | 0.130 |
Why?
| | Humans | 26 | 2022 | 115908 | 0.130 |
Why?
| | Immunoconjugates | 1 | 2017 | 87 | 0.130 |
Why?
| | B-Lymphocytes | 2 | 2015 | 771 | 0.130 |
Why?
| | Antigens, Heterophile | 1 | 2015 | 4 | 0.130 |
Why?
| | Lymphatic Irradiation | 1 | 2015 | 9 | 0.130 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1001 | 0.130 |
Why?
| | Gene Expression | 5 | 2012 | 1442 | 0.130 |
Why?
| | Lymphoma, B-Cell | 2 | 2013 | 85 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2022 | 830 | 0.120 |
Why?
| | Composite Tissue Allografts | 1 | 2014 | 8 | 0.120 |
Why?
| | Protein Biosynthesis | 2 | 2013 | 389 | 0.120 |
Why?
| | Galactosyltransferases | 2 | 2013 | 11 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 794 | 0.120 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2012 | 20 | 0.120 |
Why?
| | Lymphocyte Count | 2 | 2022 | 132 | 0.120 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2015 | 107 | 0.120 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 53 | 0.120 |
Why?
| | Mice | 10 | 2022 | 15075 | 0.120 |
Why?
| | Retinal Degeneration | 1 | 2014 | 30 | 0.120 |
Why?
| | Leukocytes | 1 | 2015 | 284 | 0.110 |
Why?
| | Plasmids | 2 | 2011 | 346 | 0.110 |
Why?
| | Antilymphocyte Serum | 1 | 2013 | 66 | 0.110 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2014 | 57 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2015 | 246 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 151 | 0.110 |
Why?
| | Somatosensory Disorders | 1 | 2012 | 1 | 0.110 |
Why?
| | Animals, Laboratory | 1 | 2012 | 13 | 0.110 |
Why?
| | Macaca mulatta | 1 | 2013 | 130 | 0.100 |
Why?
| | DNA Primers | 2 | 2012 | 513 | 0.100 |
Why?
| | Macaca | 1 | 2012 | 50 | 0.100 |
Why?
| | Glycosylation | 4 | 2013 | 133 | 0.100 |
Why?
| | Immunotherapy | 2 | 2013 | 480 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1333 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 102 | 0.100 |
Why?
| | Neoplasm Transplantation | 2 | 2013 | 235 | 0.100 |
Why?
| | Edema | 1 | 2012 | 119 | 0.100 |
Why?
| | Platelet Count | 2 | 2013 | 83 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2018 | 9166 | 0.090 |
Why?
| | Protein Binding | 5 | 2014 | 1919 | 0.090 |
Why?
| | CD40 Ligand | 1 | 2010 | 42 | 0.090 |
Why?
| | Organ Transplantation | 1 | 2013 | 161 | 0.090 |
Why?
| | Rats | 2 | 2017 | 5035 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 703 | 0.090 |
Why?
| | Antigens, CD | 2 | 2003 | 443 | 0.090 |
Why?
| | Lymphocytes | 2 | 2021 | 342 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2010 | 137 | 0.090 |
Why?
| | Prednisolone | 1 | 2010 | 77 | 0.090 |
Why?
| | Sus scrofa | 2 | 2012 | 45 | 0.090 |
Why?
| | Blood Proteins | 2 | 2022 | 238 | 0.090 |
Why?
| | Leukocytosis | 1 | 2009 | 35 | 0.090 |
Why?
| | Immunization | 1 | 2012 | 402 | 0.090 |
Why?
| | Immunophenotyping | 2 | 2007 | 273 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2012 | 295 | 0.080 |
Why?
| | Pluripotent Stem Cells | 2 | 2014 | 63 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 396 | 0.080 |
Why?
| | Bone Marrow Cells | 3 | 2006 | 272 | 0.080 |
Why?
| | Antigens | 1 | 2010 | 322 | 0.080 |
Why?
| | Anemia | 1 | 2009 | 144 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 724 | 0.080 |
Why?
| | Prognosis | 3 | 2022 | 3342 | 0.080 |
Why?
| | Macaca fascicularis | 2 | 2018 | 46 | 0.070 |
Why?
| | Varicellovirus | 1 | 2007 | 26 | 0.070 |
Why?
| | Cell Line | 3 | 2021 | 2655 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 153 | 0.070 |
Why?
| | Granulocyte Precursor Cells | 1 | 2006 | 7 | 0.070 |
Why?
| | Haploidy | 1 | 2006 | 21 | 0.070 |
Why?
| | Models, Molecular | 1 | 2011 | 1392 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1891 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2010 | 551 | 0.070 |
Why?
| | Species Specificity | 3 | 2015 | 555 | 0.070 |
Why?
| | Female | 8 | 2022 | 60086 | 0.060 |
Why?
| | Cross Reactions | 2 | 2016 | 116 | 0.060 |
Why?
| | Pregnancy | 4 | 2015 | 5556 | 0.060 |
Why?
| | Tissue Donors | 2 | 2005 | 331 | 0.060 |
Why?
| | Allografts | 2 | 2015 | 127 | 0.060 |
Why?
| | Blood Group Incompatibility | 1 | 2004 | 13 | 0.060 |
Why?
| | Models, Animal | 3 | 2015 | 350 | 0.060 |
Why?
| | Erythroid Precursor Cells | 1 | 2003 | 4 | 0.060 |
Why?
| | Blotting, Southern | 1 | 2003 | 66 | 0.060 |
Why?
| | Stem Cell Factor | 1 | 2003 | 14 | 0.060 |
Why?
| | Fetal Diseases | 1 | 2005 | 148 | 0.060 |
Why?
| | Uterus | 1 | 2005 | 193 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2003 | 16 | 0.060 |
Why?
| | Multipotent Stem Cells | 1 | 2003 | 18 | 0.060 |
Why?
| | Granulocytes | 1 | 2003 | 78 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3474 | 0.060 |
Why?
| | Blood Gas Analysis | 1 | 2023 | 69 | 0.060 |
Why?
| | Hindlimb | 1 | 2004 | 125 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2005 | 167 | 0.060 |
Why?
| | Neoplasms | 1 | 2017 | 2112 | 0.060 |
Why?
| | Blood Physiological Phenomena | 1 | 2002 | 14 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2015 | 2196 | 0.050 |
Why?
| | Oximetry | 1 | 2023 | 80 | 0.050 |
Why?
| | Binding, Competitive | 2 | 2014 | 200 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1868 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3685 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2007 | 3916 | 0.050 |
Why?
| | Gestational Age | 1 | 2005 | 757 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 41 | 0.050 |
Why?
| | Gene Knockout Techniques | 2 | 2013 | 99 | 0.050 |
Why?
| | Gammaherpesvirinae | 1 | 2002 | 38 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 71 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 95 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 123 | 0.050 |
Why?
| | Solubility | 2 | 2012 | 227 | 0.050 |
Why?
| | Fetus | 1 | 2005 | 703 | 0.050 |
Why?
| | Protein Multimerization | 2 | 2014 | 160 | 0.050 |
Why?
| | Male | 7 | 2022 | 56128 | 0.050 |
Why?
| | Genome, Viral | 1 | 2002 | 121 | 0.050 |
Why?
| | Cell Separation | 1 | 2002 | 293 | 0.050 |
Why?
| | Rabbits | 2 | 2013 | 755 | 0.050 |
Why?
| | Monocytes | 1 | 2003 | 504 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2014 | 503 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2022 | 193 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 240 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2022 | 383 | 0.040 |
Why?
| | Cytokines | 2 | 2022 | 1857 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 78 | 0.040 |
Why?
| | Viral Proteins | 1 | 2022 | 283 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 2 | 2013 | 400 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 429 | 0.040 |
Why?
| | DNA | 2 | 2017 | 1358 | 0.040 |
Why?
| | Risk | 1 | 2022 | 830 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 839 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2017 | 2606 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 481 | 0.040 |
Why?
| | Safety-Based Drug Withdrawals | 1 | 2017 | 2 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1817 | 0.040 |
Why?
| | Tumor Burden | 1 | 2017 | 261 | 0.030 |
Why?
| | Herpesvirus 1, Suid | 1 | 2015 | 1 | 0.030 |
Why?
| | Tumor Virus Infections | 1 | 2015 | 41 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 850 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2015 | 59 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2598 | 0.030 |
Why?
| | National Eye Institute (U.S.) | 1 | 2014 | 6 | 0.030 |
Why?
| | Cell Engineering | 1 | 2014 | 7 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1026 | 0.030 |
Why?
| | Regenerative Medicine | 1 | 2014 | 41 | 0.030 |
Why?
| | Random Allocation | 1 | 2014 | 338 | 0.030 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 105 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2013 | 15 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2013 | 52 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2013 | 215 | 0.030 |
Why?
| | Hematocrit | 1 | 2013 | 86 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2013 | 97 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2014 | 200 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 136 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2012 | 51 | 0.030 |
Why?
| | Drug Design | 1 | 2013 | 156 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 346 | 0.030 |
Why?
| | Lymph Nodes | 2 | 2005 | 422 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 390 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1153 | 0.020 |
Why?
| | Risk Factors | 1 | 2004 | 8714 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6267 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 308 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1728 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 449 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 945 | 0.020 |
Why?
| | Transcription, Genetic | 2 | 2007 | 1318 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 872 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 114 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2007 | 219 | 0.020 |
Why?
| | Middle Aged | 2 | 2022 | 27084 | 0.020 |
Why?
| | Splenectomy | 1 | 2005 | 54 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12616 | 0.020 |
Why?
| | Risk Assessment | 1 | 2014 | 3004 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4769 | 0.020 |
Why?
| | Adult | 2 | 2022 | 30820 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 252 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1044 | 0.010 |
Why?
| | Aged | 1 | 2022 | 19299 | 0.010 |
Why?
| | Creatinine | 1 | 2005 | 431 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 561 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 277 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1486 | 0.010 |
Why?
| | Hybridomas | 1 | 2002 | 230 | 0.010 |
Why?
| | Genes, Viral | 1 | 2002 | 89 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 352 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2002 | 328 | 0.010 |
Why?
| | Benzimidazoles | 1 | 2002 | 137 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2002 | 522 | 0.010 |
Why?
| | Bone and Bones | 1 | 2004 | 283 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 302 | 0.010 |
Why?
| | Mammals | 1 | 2002 | 251 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 866 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2581 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 733 | 0.010 |
Why?
| | Kidney | 1 | 2005 | 1208 | 0.010 |
Why?
| | Phylogeny | 1 | 2002 | 802 | 0.010 |
Why?
| | United States | 1 | 2014 | 12338 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2333 | 0.010 |
Why?
|
|
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|